Identification of CENPM as a key gene driving adrenocortical carcinoma metastasis via physical interaction with immune checkpoint ligand FGL1

Abstract

	•CENPM is the key gene that drives ACC metastasis, and a robust biomarker for ACC prognosis.
	•Silencing CENPM impedes ACC metastasis in vitro and in vivo by physical interaction with immune checkpoint ligand FGL1.
	•FGL1 is overexpressed in ACC and promotes ACC metastasis.

Keywords

adrenocortical carcinoma / CENPM / FGL1 / metastasis

References

[1] Gara SK, Lack J, Zhang L, Harris E, Cam M, Kebebew E. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nat Commun. 2018;9(1):4172.

[2] Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169(6):891-899.

[3] Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-G46.

[4] Erickson LA, Rivera M, Zhang J. Adrenocortical carcinoma: review and update. Adv Anat Pathol. 2014;21(3):151-159.

[5] Stigliano A, Cerquetti L, Lardo P, Petrangeli E, Toscano V. New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review). Oncol Rep. 2017;37(3):1301-1311.

[6] Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):208-214.

[7] Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607-612.

[8] Juhlin CC, Goh G, Healy JM, et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab. 2015;100(3):E493-502.

[9] Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29(5):723-736.

[10] Parra MT, Gomez R, Viera A, et al. Sequential assembly of centromeric proteins in male mouse meiosis. PLoS Genet. 2009;5(3):e1000417.

[11] Vargiu G, Makarov AA, Allan J, Fukagawa T, Booth DG, Earnshaw WC. Stepwise unfolding supports a subunit model for vertebrate kinetochores. Proc Natl Acad Sci U S A. 2017;114(12):3133-3138.

[12] Pesenti ME, Raisch T, Conti D, et al. Structure of the human inner kinetochore CCAN complex and its significance for human centromere organization. Mol Cell. 2022;82(11):2113-2131 e8.

[13] Singh P, Pesenti ME, Maffini S, et al. BUB1 and CENP-U, primed by CDK1, are the main PLK1 kinetochore receptors in mitosis. Mol Cell. 2021;81(1):67-87 e9.

[14] Tomonaga T, Matsushita K, Ishibashi M, et al. Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy. Cancer Res. 2005;65(11):4683-4689.

[15] Takada M, Zhang W, Suzuki A, et al. FBW7 loss promotes chromosomal instability and tumorigenesis via cyclin E1/CDK2-mediated phosphorylation of CENP-A. Cancer Res. 2017;77(18):4881-4893.

[16] Tucker JB, Carlsen CL, Scribano CM, Pattaswamy SM, Burkard ME, Weaver BA. CENP-E inhibition induces chromosomal instability and synergizes with diverse microtubule-targeting agents in breast cancer. Cancer Res. 2024;84:2674-2689.

[17] Wang Q, Xu J, Xiong Z, et al. CENPA promotes clear cell renal cell carcinoma progression and metastasis via Wnt/beta-catenin signaling pathway. J Transl Med. 2021;19(1):417.

[18] Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J Exp Clin Cancer Res. 2021;40(1):390.

[19] Lou Y, Lu J, Zhang Y, et al. The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. Cancer Lett. 2022;532:215599.

[20] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

[21] Ma J, Chen T, Wu S, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47(D1):D1211-D1217.

[22] Chen T, Ma J, Liu Y, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50(D1):D1522-D1527.

[23] Basilico F, Maffini S, Weir JR, et al. The pseudo GTPase CENP-M drives human kinetochore assembly. Elife. 2014;3:e02978.

[24] Chen J, Wu F, Shi Y, et al. Identification of key candidate genes involved in melanoma metastasis. Mol Med Rep. 2019;20(2):903-914.

[25] Xiao Y, Najeeb RM, Ma D, Yang K, Zhong Q, Liu Q. Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res. 2019;38(1):458.

[26] Zheng C, Zhang T, Li D, et al. Upregulation of CENPM facilitates tumor metastasis via the mTOR/p70S6K signaling pathway in pancreatic cancer. Oncol Rep. 2020;44(3):1003-1012.

[27] Liu C, Wang Y, Dao Y, et al. Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2022;54(1):99-112.

[28] Xie W, Zhang L, Shen J, Lai F, Han W, Liu X. Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis. BMC Cancer. 2024;24(1):551.

[29] Libe R. Clinical and molecular prognostic factors in adrenocortical carcinoma. Minerva Endocrinol. 2019;44(1):58-69.

[30] Vezzosi D, Do Cao C, Hescot S, et al. Time until partial response in metastatic adrenocortical carcinoma long-term survivors. Horm Cancer. 2018;9(1):62-69.

[31] Lalli E, Luconi M. The next step: mechanisms driving adrenocortical carcinoma metastasis. Endocr Relat Cancer. 2018;25(2):R31-R48.

[32] Ghosh C, Hu J, Kebebew E. Advances in translational research of the rare cancer type adrenocortical carcinoma. Nat Rev Cancer. 2023;23(12):805-824.

[33] Borges KS, Pignatti E, Leng S, et al. Wnt/beta-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene. 2020;39(30):5282-5291.

[34] Batisse-Lignier M, Sahut-Barnola I, Tissier F, et al. P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model. Oncogene. 2017;36(31):4445-4456.

[35] Berthon A, Sahut-Barnola I, Lambert-Langlais S, et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet. 2010;19(8):1561-1576.

[36] Gaujoux S, Grabar S, Fassnacht M, et al. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2011;17(2):328-336.

[37] Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430-439.

[38] Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36(3):171-198.

[39] Kai F, Drain AP, Weaver VM. The extracellular matrix modulates the metastatic journey. Dev Cell. 2019;49(3):332-346.

[40] Rygiel TP, Stolte EH, de Ruiter T, van de Weijer ML, Meyaard L. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol Immunol. 2011;49(1-2):402-406.

[41] Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80-96.

[42] Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1-2):334-347.

[43] Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14(1):147.

[44] Xi F, Sun H, Peng H, et al. Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells. JCI Insight. 2024;9(13).

[45] Liu TY, Yan JS, Li X, et al. FGL1: a novel biomarker and target for non-small cell lung cancer, promoting tumor progression and metastasis through KDM4A/STAT3 transcription mechanism. J Exp Clin Cancer Res. 2024;43(1):213.

[46] Huang S, Zhang J, He P, et al. Radiation-induced upregulation of FGL1 promotes esophageal squamous cell carcinoma metastasis via IMPDH1. BMC Cancer. 2024;24(1):557.

[47] Li JJ, Wang JH, Tian T, et al. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Nat Commun. 2023;14(1):6690.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.